What is InflaRx N.V.?
, a clinical-stage biopharmaceutical company, discovers and develops inhibitors using C5a technology in Germany and the United States.
The story behind the price, the case for and against, and what could go wrong. Open a part to read it.
, a clinical-stage biopharmaceutical company, discovers and develops inhibitors using C5a technology in Germany and the United States. The company's C5a is an inflammatory mediator to treat variety of autoimmune and other inflammatory diseases. The company is listed on the NASDAQ in USA, operating in the Healthcare sector, with a market capitalisation of 155.47M.
A short list of Biotechnology names that are close enough in size to make side-by-side comparison useful.